dr stephen schuster outlines car t results seen in leukemia, lymphoma, and myeloma
Published 6 years ago • 197 plays • Length 2:32Download video MP4
Download video MP3
Similar videos
-
2:22
dr stephen schuster on institution commitments to deliver car t therapies
-
2:27
dr stephen schuster: unique car t toxicities require provider education
-
17:10
prof. stephen j. schuster, m.d.: ctl019 in r/r dlbcl – interim results interview from icml 2017
-
2:03
dr. schuster dicsusses car t-cell therapy in dlbcl
-
0:46
challenges associated with the use of off-the-shelf car-t products in multiple myeloma
-
1:11
dr. madduri on eligibility for car t-cell therapy in myeloma
-
0:36
promise of gprc5d-targeted car-t therapies in multiple myeloma
-
6:55
potential for car t-cell therapy in b-cell lymphomas
-
1:21
developing off-the-shelf car t-cells to treat multiple myeloma
-
0:53
is transplantation superior to car-t therapy in multiple myeloma?
-
9:48
the use of car t-cells in multiple myeloma
-
1:49
rehabilitation needs of patients with multiple myeloma undergoing car-t therapy
-
6:18
what to expect with car t cell therapy and bispecifics in myeloma (2022) | dr. joshua richter
-
4:44
accessing myeloma car t-cell therapy clinical trials
-
1:51
how quickly can a patient see a response with car-t cell therapy? #myeloma
-
6:44
cost effectiveness and future of car t therapy
-
6:59
car t-cell therapy in hard-to-treat multiple myeloma produces sustained remissions
-
3:28
challenges in access to commercial car-t therapies in multiple myeloma
-
0:50
car-t in multiple myeloma: cilta-cel & ide-cel